Netherlands
Myriad Genetics Inc (MYGN) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Raised Financial Guidance
Revenue Growth: 15% increase in Q2 2024 compared to last year.Gross Profit: 17% increase in Q2 2024.Adjusted EBITDA: $12 million in Q2 2024.Adjusted EPS: $0.05